Antiepilepticthatdisplaysdistinctivepropertiesfromconventionalantiepilepticdrugs.Displayspotentseizureprotectioninanimalmodelsofchronicepilepsybutlacksactivityinacuteseizuremodels.Bindssynapticvesicleprotein2A(SV2A)andinhibitsNa+-dependentCl-/HCO3-exchange.
LevetiracetamisalsoofferedaspartoftheTocriscreenPlusandTocriscreenLibraryofFDA-ApprovedCompounds.FindoutmoreaboutcompoundlibrariesavailablefromTocris.
M.Wt | 170.21 |
Formula | C8H14N2O2 |
Storage | StoreatRT |
Purity | ≥99%(HPLC) |
CASNumber | 102767-28-2 |
PubChemID | 5284583 |
InChIKey | HPHUVLMMVZITSG-LURJTMIESA-N |
Smiles | O=C1N([C@@H](CC)C(N)=O)CCC1 |
Thetechnicaldataprovidedaboveisforguidanceonly.ForbatchspecificdatarefertotheCertificateofAnalysis.
AllTocrisproductsareintendedforlaboratoryresearchuseonly.
Solvent | MaxConc.mg/mL | MaxConc.mM | |
---|---|---|---|
Solubility | |||
DMSO | 17.02 | 100 | |
water | 17.02 | 100 |
Thefollowingdataisbasedontheproductmolecularweight170.21.Batchspecificmolecularweightsmayvaryfrombatchtobatchduetosolventofhydration,whichwillaffectthesolventvolumesrequiredtopreparestocksolutions.
Concentration/SolventVolume/Mass | 1mg | 5mg | 10mg |
---|---|---|---|
1mM | 5.88mL | 29.38mL | 58.75mL |
5mM | 1.18mL | 5.88mL | 11.75mL |
10mM | 0.59mL | 2.94mL | 5.88mL |
50mM | 0.12mL | 0.59mL | 1.18mL |